Dynamics of Prolyl Hydroxylases Levels During Disease Progression in Experimental Colitis
- PMID: 31377947
- PMCID: PMC6856031
- DOI: 10.1007/s10753-019-01065-3
Dynamics of Prolyl Hydroxylases Levels During Disease Progression in Experimental Colitis
Abstract
Hypoxia inducible factor (HIF)-prolyl hydroxylase (PHD) inhibitors are shown to be protective in several models of inflammatory bowel disease (IBD). However, these non-selective inhibitors are known to inhibit all the three isoforms of PHD, i.e. PHD-1, PHD-2 and PHD-3. In the present report, we investigated the associated changes in levels of PHDs during the development and recovery of chemically induced colitis in mice. The results indicated that in the experimental model of murine colitis, levels of both, PHD-1 and PHD-2 were found to be increased with the progression of the disease; however, the level of PHD-3 remained the same in group of healthy controls and mice with colitis. Thus, the findings advocated that inhibitors, which inhibited all three isoforms of PHD could not be ideal therapeutics for IBD since PHD-3 is required for normal gut function. Hence, this necessitates the development of new compounds capable of selectively inhibiting PHD-1 and PHD-2 for effective treatment of IBD.
Keywords: colitis; disease activity index; inflammatory bowel disease; prolyl hydroxylases.
Conflict of interest statement
The authors declare that they have no conflict of interest.
Figures
Similar articles
-
Recent Advances in Developing Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylases and Their Therapeutic Implications.Molecules. 2015 Nov 19;20(11):20551-68. doi: 10.3390/molecules201119717. Molecules. 2015. PMID: 26610437 Free PMC article. Review.
-
Contribution of epithelial innate immunity to systemic protection afforded by prolyl hydroxylase inhibition in murine colitis.Mucosal Immunol. 2014 Jan;7(1):114-23. doi: 10.1038/mi.2013.29. Epub 2013 May 22. Mucosal Immunol. 2014. PMID: 23695513 Free PMC article.
-
Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-_target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor.Kidney Int. 2017 Oct;92(4):900-908. doi: 10.1016/j.kint.2017.03.008. Epub 2017 May 12. Kidney Int. 2017. PMID: 28506759 Free PMC article.
-
Prolyl Hydroxylase Inhibitors: a New Opportunity in Renal and Myocardial Protection.Cardiovasc Drugs Ther. 2022 Dec;36(6):1187-1196. doi: 10.1007/s10557-021-07257-0. Epub 2021 Sep 17. Cardiovasc Drugs Ther. 2022. PMID: 34533692 Review.
-
Discovery of Novel and Potent Prolyl Hydroxylase Domain-Containing Protein (PHD) Inhibitors for The Treatment of Anemia.J Med Chem. 2024 Jan 25;67(2):1393-1405. doi: 10.1021/acs.jmedchem.3c01932. Epub 2024 Jan 8. J Med Chem. 2024. PMID: 38189253
Cited by
-
Expression of HIF1α in intestinal epithelium restricts arthritis inflammation by inhibiting RIPK3-induced cell death machinery.Ann Rheum Dis. 2024 Jul 15;83(8):984-997. doi: 10.1136/ard-2023-224491. Ann Rheum Dis. 2024. PMID: 38503474 Free PMC article.
-
T-scans in implant procedures.Bioinformation. 2023 Jan 31;19(1):35-38. doi: 10.6026/97320630019035. eCollection 2023. Bioinformation. 2023. PMID: 37720290 Free PMC article.
-
Anti-inflammatory and cytotoxic effect of lycopene and raspberry in-situ gel.Bioinformation. 2022 Jul 31;18(7):645-650. doi: 10.6026/97320630018645. eCollection 2022. Bioinformation. 2022. PMID: 37313050 Free PMC article.
-
Hypoxia inducible factor prolyl hydroxylases in inflammatory bowel disease.Front Pharmacol. 2023 May 2;14:1045997. doi: 10.3389/fphar.2023.1045997. eCollection 2023. Front Pharmacol. 2023. PMID: 37201028 Free PMC article. Review.
-
Gold nanoparticles-embedded ceria with enhanced antioxidant activities for treating inflammatory bowel disease.Bioact Mater. 2023 Jan 26;25:95-106. doi: 10.1016/j.bioactmat.2023.01.015. eCollection 2023 Jul. Bioact Mater. 2023. PMID: 36789001 Free PMC article.
References
-
- Cummins EP, Berra E, Comerford KM, Ginouves A, Fitzgerald KT, Seeballuck F, Godson C, Nielsen JE, Moynagh P, Pouyssegur J, Taylor CT. Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. Proceedings of the National Academy of Sciences of the United States of America. 2006;103:18154–18159. doi: 10.1073/pnas.0602235103. - DOI - PMC - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources